Introduction
Metal-on-polyethylene (MoP) total hip arthroplasty (THA) was the gold standard in bearing surfaces for the treatment of end-stage osteoarthritis through the late 1990s. This period then saw a resurgence in the use of metal-on-metal (MoM) bearings. Metal components facilitated the use of larger head sizes which offered lower volumetric wear rates, lower implant fracture risk, lower dislocation rates, and higher range of motion (1) . In light of this movement, DePuy introduced the largediameter head MoM Articular Surface Replacement (ASR) Hip System (ASR XL THA and ASR hip resurfacing) in 2003. More than 93,000 devices were implanted worldwide (2) .
We have conducted a review of our prospective, multicentre study monitoring the ASR XL prosthesis with the objective to assess the associations between gender and implant survival, as well as ALTR, in ASR MoM THA patients. Secondly, we sought to report the differences between genders in metal ion levels and patient reported outcome measures (PROMs) in these patients.
Methods
We performed a prospective, multicentre study of the ASR Hip System (DePuy Orthopaedics). Patients were enrolled after obtaining IRB approval and subsequently followed annually up to and including their revision event, if applicable. The study was initiated after the recall of the ASR Hip System; however, data were collected prospectively with the aim of assessing potential predictors for various outcomes including ALTRs, revision surgery, and PROMs.
Data were collected between September 2012 and March 2016 at Massachusetts General Hospital, MA, USA, from 16 participating sites located in 6 countries (United States, United Kingdom, Denmark, Italy, South Africa, and Australia) through a secure, web-based data entry system. Data collected included head size, blood metal ion levels, PROMs, patient and surgery details, presence of ALTR (if magnetic resonance imaging [MRI] was available), presence or absence of revision surgery and revision indication, and AP pelvis radiographs for measurement of cup position. Blood metal ion levels and PROMs were collected annually. Radiographs were collected at the time of enrollment for all patients and at subsequent intervals if clinically indicated.
The study population consisted of 724 ASR XL THA patients (Fig. 1) . These patients met the following inclusion criteria: any patient (i) with on-label use of ASR XL THA currently implanted; (ii) able to give informed consent as approved by the ethics committee; (iii) able to return for annual follow-up for a period of 5 years; and (iv) able to complete the required PROMs. For our analyses, we divided the hips into 2 cohorts.
In Cohort A, we included only ASR XL patients that had complete enrollment data as dictated by the study protocol: (i) demographic information; (ii) surgical demographic information; (iii) blood metal ion levels (chromium and cobalt) within 6 months of consent; (iv) PROMs within 6 months of consent; (v) a valid AP pelvis plain radiograph dating a maximum of 2 years before consent; and (vi) notification of and reason for revision, if applicable. This yielded 563 patients (563 hips) for Cohort A. The mean age of Cohort A at the time of index surgery was 61 years (range 22-95 years) and 261 were women (46%). The mean time from index surgery to follow-up was 6.4 years (range 3-11 years). The mean time from index surgery to follow-up did not differ between males and females (p = 0.133) (Tab. I). The median femoral head size for female patients was 46 mm (range 39-57 mm) and 51 mm for males (range 39-59 mm; p<0.001) (Tab. II).
Cohort B was a subset of Cohort A; it included all patients from Cohort A with unilateral THA that came from a single centre where metal artifact reduction sequence (MARS) protocol MRI is annually performed (11) . 114 patients (131 hips) out of the 128 patients (148 hips) undergoing annual followup at this centre had MRI performed. 97 of these patients had unilateral THA and comprised Cohort B. There were 58 males (60%) and 39 females (40%).
The PROMs were collected annually and included the EuroQoL 5 dimensions questionnaire (EQ-5D) (12) to indicate health-related quality of life, the Harris Hip Score (HHS) to indicate hip function, University of California at Los Angeles (UCLA) activity score, and visual analogue scale (VAS) pain (0-10). The level of anxiety/depression in patients receiving the ASR was assessed using the anxiety/depression domain of the EQ-5D questionnaire and the responses were dichotomised into no anxiety or any anxiety (moderate/severe). The cup inclination angle of the acetabular component was measured for each hip from collected radiographs using mDesk software (RSA Biomedical) by 3 trained and validated observers.
MR images were assessed for the presence, location, and severity of ALTRs. The severity was classified using the Anderson grading system (11, 13) . MRI assessment was performed by 1 of the authors (R.M.) with 2 years of experience and was validated by a musculoskeletal radiologist (H.P.) with more than 10 years of experience reading MARS MRIs. This assessment was blinded to all clinical and surgical patient data.
Whole blood cobalt and chromium metal ion concentrations were obtained annually at certified laboratories using a standardized protocol and reported in parts per billion (ppb).
Statistical analysis
Student's t-test for 2 independent samples was used to compare normally distributed variables and a Mann-Whitney U-test was used for continuous variables that did not follow a normal distribution. The chi-square test was used in the assessment of categorical variables. Cumulative revision rates (CRRs) were calculated using the Kaplan-Meier survival method and compared using the log-rank test. We calculated relative risk of revision using Cox proportional hazards for which the proportional hazards assumption was met in all analyses. The following independent variables were included: female gender, blood chromium level, blood cobalt level, femoral stem type, acetabular inclination angle, age at index surgery, head size, HHS, EQ-5D, UCLA score, VAS pain, and EQ-5D anxiety/depression. Stem type was categorised into multiple groups; Summit Porous, Corail, S-ROM, Proxima and Other (Tab. II). The 'other' group contained AML, Tri-Lock, Replica, and unidentified stem types. Acetabular inclination angle was categorised into 2 groups; steep inclination angle (≥55°) or nonsteep inclination angle (<55°). The same methods, as well as the same independent risk factors were used for Cohort B to assess the relationship between moderate/severe ALTR. ALTRs were categorised as a dichotomous outcome variable with moderate-to-severe ALTRs classified as complications. Interobserver reliability for the assessment of ALTR grade was performed using Cohen's kappa (κ) and was substantial (κ = 0.64). A p value <0.05 was considered significant. Statistical analyses were performed using SPSS Version 17.0 (SPSS Inc.).
Results

Sex/gender and implant survival and ALTR
60 hips (11%) were revised during the study period. 31 of the 302 men (10%) and 29 of the 261 women underwent revision (11%). The mean time from index surgery to revision was 7 years for both males and females (p = 0.565). No revisions were performed for infection. Multiple reasons for revision were reported, including bony tissue necrosis (n = 9), MRIverified soft tissue change (n = 31), patient demand (n = 18), aseptic loosening (n = 6), osteolysis (n = 20), physician recommendation (n = 40), dislocation (n = 2), and pain (n = 39). Patient demand and physician recommendation were always accompanied by another clinical indicator for revision.
The only variables found to be associated with revision surgery in unilateral patients were VAS pain (hazard ratio [HR], 1.35; CI, 1.18-1.55, p<0.001) and cobalt metal ion levels (HR, 1.05; CI, 1.03-1.08; p<0.001) (Tab. III). In patients with annual MARS MRI, moderate-to-severe ALTRs were identified in 38 of the 97 hips (39%), 12 of which were in female patients (31% of females) and 26 in male patients (45% of males). None of the explanatory variables assessed were found to be associated with the presence of moderate-to-severe ALTR.
Sex/gender and metal ion levels and PROMs
Chromium concentrations were greater in female patients than in males (chromium, median 1.9 ppb versus 1.4 ppb, p<0.001), while cobalt levels were similar for females (median 3.4 ppb, range 0-142.9 ppb) and males (median 2.5 ppb, range 0-58.9 ppb, p = 0.060) (Tab. IV). Males reported a higher EQ-5D (median, 0.94 vs. 0.80, p = 0.005) and UCLA activity score (median, 6 vs. 7, p<0.001) than females; however, there was no difference between HHS (median, 92 vs. 91, p = 0.083) and VAS pain (median, 0.5 vs. 0.5, p = 0.624) (Tab. IV).
Discussion
Regulatory agencies, such as the US FDA and UK MHRA, have published recommended guidelines for the follow-up of MoM patients. Scientific literature and clinical experience have identified the need for further development of an optimal follow-up protocol (14, 15) . As thousands of MoM THA patients are still undergoing follow-up it remains critical to determine risk factors for complications such as revision surgery and prevalence of ALTR. Many studies have identified female gender as a risk factor for revision surgery in MoM HRA; however, less research has been dedicated to assessing this association in patients with MoM THA. As these are known to be 2 distinctly different patient populations, further investigation of this relationship is warranted in MoM THA patients (10) .
In patients with ASR XL THA, female gender was not found to be associated with revision surgery or prevalence of ALTR. Only elevated cobalt levels and high VAS pain scores were predictive of revision surgery in unilateral ASR XL patients.
The hazard ratio, although statistically significant, was quite small for cobalt levels (1.05) and should be observed with caution. None of the assessed explanatory variables were associated with a higher prevalence of ALTR.
Other studies have also found female gender not to be a significant risk factor for revision surgery in MoM THA (5, 16, 17) . In the follow-up of 94 ASR XL THA patients, Cip et al (16) found only steep inclination angle (>50°) to be a risk factor for early THA failure. Another study defining hip failure as revision surgery, intention to revise, or poor hip function found the only independent predictor of hip failure to be metal ion levels (the maximum value of either cobalt or chromium) (17) . Our findings were partially consistent with this study as we also found only elevated cobalt levels to be predictive of revision surgery. There are few other studies that have fully examined the association between female gender and implant failure in patients with MoM THA. In fact, Haughom et al (10) recognised such a dearth of literature on this topic that they were forced to abandon their efforts conducting a systematic literature review and instead only reported the results of studies exploring female gender as a predictor of implant failure in MoM HRA.
We did not observe any association between female gender and prevalence of ALTR. Previous studies have produced conflicting results on the relationship between female gender and pseudotumour development. 1 study assessing a MoM acetabular component identified female gender and elevated cobalt levels (≥5 ppb) as predictors of pseudotumour (8) . Similar results were confirmed in a cohort of unilateral ASR XL patients as abnormal plasma cobalt levels (≥5 ppb) were associated with the presence of pseudotumour (9) . As we failed to find an association between elevated metal ion levels and ALTR, our findings emphasise the need to use them in combination with other parameters in clinical follow-up and screening for ALTR. Reito et al (7) identified in both smalland large-headed cohorts, patients with Corail stems were approximately 2-times more likely to present with ARMD (18) . In our patient cohort, the association between stem types and ALTR did not reach statistical significance; however, as we only studied 97 patients with MRI, we may not have a large enough distribution of stem types to accurately identify differences between these groups. Elevated chromium levels were observed in female patients compared with males. Cobalt levels tended to be higher in women, as well, however, this trend did not reach statistical significance. Men reported higher HHS, higher EQ-5D, and higher UCLA activity levels; however, these differences did not reach minimally clinical important differences (MCID). The EQ-5D has been shown to have a mean MCID in total hip arthroplasty patients of 0.31 (19) , while the HHS has an MCID of 7-9 (20) . There is no established MCID for the UCLA activity score. These results are mostly consistent with previous literature (16, 21) . As the femoral head size distribution is known to be different in male and female THA patients, Bayley et al (22) conducted a study of 191 MoM THA hips to determine if female gender was associated with elevated metal ion levels while controlling for other confounders such as BMI and femoral head size. They found small femoral head size, bilateral MoM THA, and female sex to be associated with elevated cobalt levels, while only small femoral head size, bilateral MoM THA, and lower BMI were associated with elevated chromium levels (22) . We observed that our patients with MoM THA have higher Cobalt levels compared to Chromium and other studies with similar results have hypothesized that it is likely that this relates to the corrosion at the taper junction rather than wear of the articulating surface (9, 17) . Metal debris production originating from the taper instead of the articulating surface could explain why we did not see an effect of steep inclination angle on metal ion levels in our multivariate analysis.
Our study had some limitations. Firstly, we are reporting on a complex patient group who are fitted with a recalled device that is known to have higher failure rates than other THA implants (3, 5) . This limits our ability to extend our observations from this study to other MoM devices as revisions in this patient population are likely a multifactorial decision involving measures that cannot be obtained clinically. Secondly, the patients included in this study were not revised prior to the voluntary recall issued by DePuy, therefore our data cannot be used to recognise reasons for early failure in ASR XL THA. However, we are capturing data on ASR XL patients that are still undergoing follow-up, which is important as we try to better understand the mid-to late-term consequences of the ASR XL implant. Lastly, as MARS MRI was not performed on all patients in the study, presence of ALTR could not be included in the analysis of revision as an outcome.
To our knowledge, this is the largest multicentre analysis exploring the association between female gender and revision surgery in ASR XL THA patients while controlling for relevant confounding variables. Few previous studies have fully examined the relationships between female gender and revision surgery and ALTR in MoM THA, and those that have may not be entirely applicable to the ASR device as some studies have reported the revision rate to be six times higher than other MoM THA implants (1) . Because of the difference in prosthesis design and in revision rates, it might be unwise to compare the ASR XL implant with other MoM THA devices.
We believe our study offers a robust analysis of the risk factors for revision surgery in patients with the ASR XL implant. Female gender was not identified as a risk factor for revision surgery or ALTR in these patients; however, as this implant is known to be different from other MoM THA devices, our results should be observed with caution when comparing to other MoM THA implants. Future research efforts should work to contribute to a growing body of evidence on the risk factors of revision surgery in the mid-to-late term follow-up of MoM THA patients as thousands of these patients continue routine follow-up.
